JP2006519852A5 - - Google Patents

Download PDF

Info

Publication number
JP2006519852A5
JP2006519852A5 JP2006507175A JP2006507175A JP2006519852A5 JP 2006519852 A5 JP2006519852 A5 JP 2006519852A5 JP 2006507175 A JP2006507175 A JP 2006507175A JP 2006507175 A JP2006507175 A JP 2006507175A JP 2006519852 A5 JP2006519852 A5 JP 2006519852A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
salt
carbon atoms
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006507175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006519852A (ja
Filing date
Publication date
Priority claimed from US10/402,347 external-priority patent/US7022712B2/en
Application filed filed Critical
Priority claimed from PCT/US2004/007786 external-priority patent/WO2004081006A1/en
Publication of JP2006519852A publication Critical patent/JP2006519852A/ja
Publication of JP2006519852A5 publication Critical patent/JP2006519852A5/ja
Pending legal-status Critical Current

Links

JP2006507175A 2003-03-12 2004-03-12 弱塩基の塩 Pending JP2006519852A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45403503P 2003-03-12 2003-03-12
US45451403P 2003-03-13 2003-03-13
US10/402,347 US7022712B2 (en) 2002-03-26 2003-03-26 Solubilization of weak bases
PCT/US2004/007786 WO2004081006A1 (en) 2003-03-12 2004-03-12 Weak base salts

Publications (2)

Publication Number Publication Date
JP2006519852A JP2006519852A (ja) 2006-08-31
JP2006519852A5 true JP2006519852A5 (enExample) 2007-04-19

Family

ID=32995897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006507175A Pending JP2006519852A (ja) 2003-03-12 2004-03-12 弱塩基の塩

Country Status (6)

Country Link
EP (1) EP1606290A1 (enExample)
JP (1) JP2006519852A (enExample)
AU (1) AU2004220053A1 (enExample)
CA (1) CA2515289A1 (enExample)
MX (1) MXPA05009564A (enExample)
WO (1) WO2004081006A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
SG174054A1 (en) 2006-05-04 2011-09-29 Boehringer Ingelheim Int Polymorphs
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20110067096A (ko) 2008-09-10 2011-06-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 및 관련 상태를 치료하기 위한 병용 요법
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AR074374A1 (es) * 2008-11-19 2011-01-12 Cephalon Inc Formas de un compuesto de pirrolocarbazol fusionado, composiciones que las comprenden y su uso en el tratamiento de la angiogénesis y los tumores sólidos.
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
CA2803504C (en) 2010-06-24 2022-08-30 Boehringer Ingelheim International Gmbh A combination for diabetes therapy comprising linagliptin and a long-acting insulin
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1195180A (en) * 1967-05-05 1970-06-17 Du Pont Use of Alkyl 2-Benzimidazole-Carbamate Salts a Fungicides
CA962588A (en) * 1972-05-17 1975-02-11 Her Majesty In Right Of Canada As Represented By The Minister Of The Env Ironment, And Canadian Patents And Development Limited Method, apparatus, and fungicides for the treatment of trees subject to dutch elm disease and other fungus diseases
JPS5459338A (en) * 1977-10-20 1979-05-12 Takeda Chem Ind Ltd Remedy for dermatomycosis
HU199431B (en) * 1985-02-04 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing carbendazim salts, and fungicide comprising such carbendazim salt as active ingredient
US6423734B1 (en) * 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer

Similar Documents

Publication Publication Date Title
JP2006519852A5 (enExample)
JP2008526757A5 (enExample)
JP2010509356A5 (enExample)
JP2006182786A5 (enExample)
RU2013147744A (ru) Дозированная лекарственная форма для перорального применения
JP2020507589A5 (enExample)
JP2009530398A5 (enExample)
JP2004511466A5 (enExample)
JP2008509166A5 (enExample)
EP1857457A3 (en) Benzimidazole derivative and its use as AII receptor antagonist
JP2004516314A5 (enExample)
JP2013505969A5 (enExample)
JP2005534669A5 (enExample)
JP2002516817A5 (enExample)
JP2001526218A5 (enExample)
YU36403A (sh) Soli izotiazol-4-karboksamida kao anti-hiperproliferacioni agensi
CN111295372A (zh) 硝羟喹啉前药及其用途
JP2005526024A5 (enExample)
JP2008503533A5 (enExample)
JP2005527576A5 (enExample)
JP2007505044A5 (enExample)
JP2013506004A5 (enExample)
JP2006525368A5 (enExample)
JP2004523478A5 (enExample)
JP2005510457A5 (enExample)